Adoptive Immunotherapy and High-Risk Myeloma
- Catherine Duane, Michael O’Dwyer, Siobhan Glavey, Catherine Duane, Michael O’Dwyer, Siobhan Glavey
- None, 10.3390/cancers15092633
Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment
- Hannah Egan, Oliver Treacy, Kevin Lynch, …, Philip D Dunne, Michael E O’Dwyer, Aideen E Ryan
- Cell Rep, 10.1016/j.celrep.2023.112475
Sialofucosylation Enables Platelet Binding to Myeloma Cells via P-Selectin and Suppresses NK Cell-Mediated Cytotoxicity
- Alessandro Natoni, Marina Cerreto, Maria Stefania De Propris, …, Anna Guarini, Michael O’Dwyer, Robin FoÃ
- None, 10.3390/cancers15072154
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial
- Alisa M Higgins, Lindsay R Berry, Elizabeth Lorenzi, …, Anthony C Gordon, Steve A Webb, Patrick R Lawler
- JAMA, 10.1001/jama.2022.23257
Ambient air pollutant concentrations and asthma-related hospital admissions during COVID-19 transport restrictions
- C Kelly, P Kenny, M O’Dwyer, K I Quintyne
- Public Health, 10.1016/j.puhe.2022.07.009
CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment
- D Swan, R Henderson, C McEllistrim, …, J Krawczyk, P Murphy, M O’Dwyer
- Clin Lymphoma Myeloma Leuk, 10.1016/j.clml.2022.07.011